Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3. The role of the H3.3K27M mutation in tumorigenesis is not fully understood. Here, we use a human embryonic stem cell system to model this tumor. We show that H3.3K27M expression synergizes with p53 loss and PDGFRA activation in neural progenitor cells derived from human embryonic stem cells, resulting in neoplastic transformation. Genome-wide analyses indicate a resetting of the transformed precursors to a developmentally more primitive stem cell state, with evidence of major modifications of histone marks at several master regulator genes. Drug screening assays identified a compound targeting the protein menin as an inhibitor of tumor cell growth in vitro and in mice.
D
iffuse intrinsic pontine gliomas (DIPGs) are rare, highly aggressive brainstem tumors primarily affecting children. Over 70% of DIPGs carry somatic mutations in the H3F3A gene encoding histone H3.3, leading to a p.Lys27Met amino acid substitution (methionine replaces lysine 27) (1) (2) (3) . Tumors positive for the mutation are associated with poorer prognosis and diminished survival. Comprehensive whole-genome analyses have shown that the H3.3K27M mutation identifies a distinct subgroup of DIPGs that has substantial overlap with p53 mutations and platelet-derived growth factor receptor, a polypeptide (PDGFRA) amplification (60% and 40%, respectively) (4, 5) . These genetic studies have paved the way for investigations of the pathogenesis and treatment of this rapidly fatal tumor. However, tissue access remains a substantial challenge because of the infiltrative nature and sensitive location of the tumor in the brainstem. Key features of K27M-mutated DIPGs are the restricted developmental window during which they emerge [mean age at diagnosis is 8 years (5)] and their specific midline location, which implicate a developmentally early and anatomically specific cell of origin.
We reasoned that human pluripotent stem cells (hPSCs) (6) might be a valuable model for studying DIPG. These cells provide an attractive platform for functional analysis of oncogenic mutations in a genetically defined human background. In addition, neural differentiation protocols allow the derivation of relevant developmentally early neural stem cells that are often inaccessible; thus, tumorigenesis can be studied in the proper cell context. We first derived early neural progenitor cells (NPCs) from human embryonic stem (hES) cells (H9, WA-09), using the dual Smad inhibition protocol (7) . We then cotransduced the cells with lentiviruses encoding (i) a constitutively active form of the PDGFRA in which valine replaces aspartic acid 842 (D842V); (ii), a small hairpin RNA (shRNA) against p53 tagged with red fluorescent protein (RFP); and (iii) a hemagglutinin (HA)-tagged wild-type (WT) or K27M mutant form of histone H3.3 (Fig. 1A) . These oncogenes were selected on the basis of their high frequency of expression and/or mutations in K27M-mutated DIPGs (5, 8) . After transduction and double selection under puromycin and G418, the cells maintained NPC-like morphology and expression of two NPC marker genes, Nestin and SOX2 (Fig. 1B) . Consistent with previous reports (9-11), the expression of H3.3K27M led to a reduction in histone H3K27 trimethylation (H3K27me3), as shown by immunohistochemistry and Western blotting (Fig. 1, B and C) . Expression of H3.3K27M alone increased cell proliferation (Ki-67 of~27% versus15 to 17%) and total cell number, in comparison to WT H3.3 or mock (empty vector) conditions (Fig. 1D and fig. S1A ). Overexpression of constitutively active PDGFRA (D842V) and knockdown of p53 (hereafter referred to as P5) also increased the proliferation of NPCs. The combination of H3.3K27M and P5 was even more effective in increasing the proliferative capacity of the P5 cells, up to a Ki-67 index of >30%. This result was confirmed by using a second independent shRNA against p53 (sh-p53) ( fig. S1 , B to D). The proliferative effect on neural precursors is specific to H3.3K27M and is not seen in the G34R/V mutations of H3.3 (glycine 34 is replaced by arginine or valine), which are mostly reported in supratentorial glioblastomas (Fig.  1E) . It is also highly specific to the cell context, because H3.3K27M expression in undifferentiated hES cells or in differentiated somatic cells-such as hES-derived astrocytes, primary human astrocytes, or MRC-5 human lung fibroblast cells-did not affect proliferation rates and, in some cases, induced senescence ( Fig. 1F and  fig. S2 ). Expression of Olig2, reported in DIPGs (4), was increased in both the H3.3K27M and the P5 condition ( fig. S3) .
We next explored whether the transduced NPCs had acquired features of neoplastic cells. Under low-density culture conditions, all cell groups showed poor survival, with the exception of the P5+H3.3K27M (P5K) cells, which formed robust colonies that grew to confluence, consistent with a neoplastic phenotype ( Fig. 2A and fig.  S4A ). The combination of PDGFRA, sh-p53, and H3.3K27M had a synergistic effect on cell survival. After growth factor withdrawal, the apoptotic cell fraction was higher in the H3.3K27M-expressing cells, in comparison with normal and WT H3.3-expressing NPCs (fig. S4B) ; this suggests that the proliferative effect imparted by the histone mutation was balanced with an increased apoptotic rate, a phenomenon often associated with premalignant states (12) . The introduction of p53 knockdown in the P5K condition abrogated the apoptotic response, and possibly promoting genomic instability as the cells continued to proliferate. The P5 condition also conferred greater efficiency in neurosphere formation, in all groups, including the P5K combination, whereas cells expressing only H3.3K27M were similar to unperturbed NPCs ( fig. S4C) . These results support a synergistic effect of H3.3K27M and P5 in the oncogenic transformation of NPCs, consistent with the high frequency of comutation of H3.3K27M and mutated p53 in human DIPGs (1, 4, 5) .
We also analyzed transduced NPCs for radiation response and migratory capacity. After irradiation, cells transduced with the combination of H3.3K27M and P5 maintained a high proliferation rate despite substantial DNA damage ( fig.  S4 , D to G), a hallmark of cancer cells (13) . Expression of H3.3K27M also increased cell migration ( fig. S4H ) and invasion ( fig. S4I ) in in vitro assays. High migration capacity of tumor cells is a major feature of DIPGs that renders the tumors unsuitable for surgical eradication. There was a near-complete differentiation block in the astrocytic lineage in the P5K cells, despite an extended culture period in vitro [normal NPCs acquire a capacity for robust differentiation into astrocytes (glial competence) only after several weeks in vitro] (Fig. 2B ). Note that neither the P5 nor the H3.3K27M condition alone inhibited differentiation, but the combination blocked differentiation into astrocytes and to some extent differentiation into oligodendrocytes ( fig. S5 ).
To evaluate tumor formation in vivo, we injected transduced NPCs into the brainstem (pons) of immunocompromised mice. Massive brain tumor formation occurred in the P5K mice, but not in the P5W or mock-injected mice (Fig. 2, C and D). Immunohistochemistry demonstrated human cells infiltrating the pons, with encasement of the basilar artery, microcystic changes, and subarachnoid and subventricular spread, as is often seen in patients with DIPG ( fig. S6) (14) . Tumor growth was relatively slow, with symptoms and/or substantial tumor volume appearing 3 months after injection of 500,000 cells or 5 months after injection of 100,000 cells. Phenotypic analysis of the tumor cells confirmed expression of the H3.3K27M and sh-p53 constructs (HA and RFP tags in 78% and 76.4% of all human cells, respectively) (fig. S7, A and B), as well as markers of immature NPCs (Nestin, Sox2, and Olig2) and high proliferation rates in the P5K group compared with P5W cells or normal NPCs (10.4% versus 0.7% and 0%, respectively) ( Pathologically, the tumors resembled lower-grade DIPGs and not full-blown glioblastomas (GBMs), as determined by the absence of necrosis and microvascular proliferation. We speculate that longer in vivo growth periods may be required for the accumulation of mutations leading to a more malignant phenotype. Animals bearing P5W cells showed evidence of a few cell clusters and minimal infiltration in the pons, whereas mock cell injections were associated with minimal cell survival (Fig. 2C) .
We next examined gene expression profiles of P5K cells maintained in vitro or sorted by fluorescence-activated cell sorting from Immunophenotyping of the xenografts. Immunofluorescence images and quantification for HNA, Ki67 (F and G), SOX2 (F and H) and human-specific Nestin (F). Error bars in panels (G) and (H) indicate means T SEM (n = 3 to 6). Scale bar, 20 mm. *P < 0.05; **P < 0.01; NS, not significant; ND, not detected.
tumor-bearing animals. These profiles were compared with those of patient tumors, including DIPGs with H3K27M or H3G34R/V mutations and adult GBMs without histone mutations (Fig. 3A  and fig. S8A ). Upon unsupervised hierarchical clustering, the P5K cells from in vitro or in vivo sources clustered closer to the H3K27M group (P < 4.36 × 10 −8 and P < 2.26 × 10 −4 ) than the G34R/V or GBMs without histone mutation ( fig.  S8B ). We next analyzed differentially expressed genes among the different NPC groups (Fig. 3B,  fig. S8C , and tables S1 and S2). We noted an enrichment in the K27M-expressing cells of a subset of transcripts known to be expressed in neuroepithelial cells at a very early developmental stage-i.e., the neural plate, which precedes the emergence of NPCs. To validate this finding, we derived from public datasets (GEO accession no. GSE9921) (15) S8D ). We also found a highly significant intersection of genes that were up-regulated in H3.3K27M cells with those in the rosette or rosette-human ES groups. In contrast, most of the genes that were differentially down-regulated in the H3.3K27M cells were shared with those in the NPC group ( fig. S8E ).
Reverse transcription with quantitative polymerase chain reaction (RT-qPCR) validated the increased expression of LIN28B, PLAG1, and PLAGL1 in hES cells and rosettes and substantial downregulation of all three genes in normal NPCs. Expression of H3.3K27M in NPCs up-regulated expression levels of the same genes (Fig. 3C) . Note that analysis of patient samples revealed that these genes were expressed at higher levels in DIPGs with the H3K27M mutation than in DIPGs with the G34R/V mutation or without either mutation in histone H3.3 (1) (Fig. 3D and  fig. S9 ). Knockdown of LIN28B or PLAG1 led to a significant decrease in cell number and proliferation in P5K cells ( fig. S10 ). These data suggest that expression of mutant H3.3K27M leads to a developmental resetting of neural precursors to a more primitive stem cell state, which in combination with growth factor signaling, results in the acquisition or consolidation of oncogenic features.
We next investigated whether the transcriptional changes in the K27M groups were associated with chromatin modifications. We performed chromatin immunoprecipitation followed by sequencing (ChIP-seq) analysis to map active H3K4me3 and repressive H3K27me3 marks in the P5W and P5K cells. Consistent with previous reports (11, 16) , H3K27me3 peaks undergo genomic redistribution in the P5K condition (Fig.  3E) . Notably, the genes up-regulated by K27M ) (Fig. 3E and  fig. S11, A to D) . Concomitantly, H3K4me3 peaks remained stable at promoter regions, which implied that K27M may release these genes from the poised state. On the other hand, the genes down-regulated by K27M gained H3K27me3 and lost H3K4me3 marks in P5K cells at their promoter regions (Fig. 3, E and F; fig. S11C ; and table S3). Of these, oligodendrocyte differentiation genes Nkx2.2 and MBP were highly marked by H3K27me3, and their expression levels were decreased in the NPCs expressing K27M alone or the P5K combination (Fig. 3E and fig. S11 , B and E). Master genes that initiate acquisition of astrocyte cell fate are not fully elucidated in humans and could not be analyzed. We further analyzed a set of genes that gain H3K27me3 marks in P5K and P5W cells by comparing them with reported H3K27me3 or PRC2 target genes in undifferentiated hES cells (17) . There was a highly significant intersection of P5K-specific H3K27me3-target genes with H3K27me3-target genes, as well as PRC2-target genes in ES cells (P < 2.6 × 10 −264 and P < 1.7 × 10 −219 ) ( Fig. 3G and table S4 ), whereas P5W-specific H3K27me3-target genes have no significant intersection. These data support our hypothesis that the expression of K27M leads to a resetting of neural precursors to a more primitive stem cell state. To explore whether the hES-based tumor model can be used for drug discovery, we performed a chemical screen using a commercially available small-molecule library of compounds that target epigenetic regulators (n = 80), such as BET bromodomain inhibitors, deacetylase and demethylase inhibitors, including selective JMJD3 inhibitors (table S5 and the methods section of supplementary materials). Green fluorescent protein (GFP)-labeled normal NPCs and RFP-labeled P5K cells were mixed and seeded onto 96-well plates. Cells were then treated with each compound at eight different concentrations for 6 days, and GFP and RFP fluorescence was quantified by a plate reader (Fig. 4A) . The top hit was the menin inhibitor MI-2 (18), which reduced survival of P5K cells at submicromolar concentrations [median inhibitory concentration (IC 50 ) = 155 nM] but had no effect on normal NPCs (Fig. 4B, fig  S12A, and table S5 ). The effect of MI-2 on cell survival was independent of the P5 combination and was restricted to cells with the H3K27M mutation (Fig. 4, C and D) (fig. S12, B to D) . shRNA-mediated silencing of the gene encoding menin (MEN1) resulted in decreased proliferation of P5K but not P5W cells (Fig. 4E and fig.  S12 , E to H). It also restored astrocytic differentiation in P5K cells ( fig. S12, I and J), which suggests that a common mechanism underlies the major transformation features, i.e., proliferation and impaired differentiation. Menin is expressed in undifferentiated hES cells and rosettes, but its levels decrease in normal NPCs and astrocytes; however, expression of the P5K combination in NPCs increases menin transcription sixfold ( fig  S13) . Pontine injections of P5K cells transduced with shRNA against menin resulted in significantly reduced tumor formation in mice (fig. S14A). We also tested the impact of systemic treatment with MI-2 on tumor growth in vivo. To this end, we injected P5K cells transduced with a luciferase vector in the brainstem of a large group of mice (n = 26), monitored for tumor development via bioluminescence imaging (BLI), then started treatment with intraperitoneal injections of MI-2. Control mice received tumor cell injections in the brain but were treated with dimethyl sulfoxide (DMSO) intraperitoneally. After 4 weeks of drug treatment, the MI-2 group demonstrated significantly smaller tumors by BLI (P = 0.026) (Fig. 4F and fig. S14B ) in comparison with the DMSO group. We also live-sorted P5K cells from mouse tumors and tested their response to MI-2. The cells exhibited a decrease in cell survival and proliferation and increased apoptosis, similar to P5K cells that were never injected in mice ( fig. S15 ). P5K cells live-sorted from mouse tumors also exhibited a decrease in cell survival when LIN28B or PLAGL1 are silenced ( fig. S15H ). Finally, we tested MI-2 on cell cultures derived from a patient sample. Cells from a human DIPG positive for the H3.3K27M mutation showed a robust antiproliferative response (Fig. 4G and fig. S16 ). Menin plays a tumorsuppressor role in endocrine cancers but is highly oncogenic in mixed lineage-associated leukemias (19, 20) . It is a member of the trithorax family histone methyltransferase complex but also interacts with a wide range of proteins and is thought to be involved in transcriptional regulation. Our data suggest that it may be a potential therapeutic target for pediatric gliomas harboring the H3.3K27M mutation.
In summary, using hES cells as a platform to model diffuse intrinsic gliomas, we demonstrate a driver role of the H3.3K27M mutation in the appropriate cell context and developmental window; the model also showed that the altered chromatin landscape induced by H3K27M facilitates the reacquisition of an earlier developmental program with subsequent activation of factors crucial to reprogramming and oncogenesis, such as the micro-RNA binding protein LIN28B (21) . A chemical screen identified the menin pathway as a contributor to tumor maintenance, which provides a potential opportunity for therapeutic intervention. Variability in gene expression among genetically identical cells has emerged as a central preoccupation in the study of gene regulation; however, a divide exists between the predictions of molecular models of prokaryotic transcriptional regulation and genome-wide experimental studies suggesting that this variability is indifferent to the underlying regulatory architecture. We constructed a set of promoters in Escherichia coli in which promoter strength, transcription factor binding strength, and transcription factor copy numbers are systematically varied, and used messenger RNA (mRNA) fluorescence in situ hybridization to observe how these changes affected variability in gene expression. Our parameter-free models predicted the observed variability; hence, the molecular details of transcription dictate variability in mRNA expression, and transcriptional noise is specifically tunable and thus represents an evolutionarily accessible phenotypic parameter.
T he single-molecule events underlying gene expression, such as transcription factor binding and unbinding or RNA polymerase (RNAP) open complex formation, are inherently stochastic-a stochasticity inherited by gene expression itself. Over the past decade, theorists have sought to elucidate how changes in molecular kinetic parameters such as transcription factor binding and unbinding rates affect variability in expression (1, 2), whereas experimentalists have measured variability in gene expression at both the mRNA and protein level in prokaryotes and eukaryotes (3) (4) (5) (6) . Possible phenotypic consequences (4, 7-9) include the intriguing hypothesis that transcriptional noise may increase the fitness of microbial populations by providing phenotypic variability in a population of genetically identical cells (10, 11) .
Models of transcription hinge on the molecular details of the promoter architecture (where "promoter architecture" refers collectively to the locations and strengths of transcription factor and RNAP binding sites governing a particular gene) and make quantitative predictions for the dependence of the variability on these details. For example, two extremely common promoter architectures (12) are shown schematically in Fig. 1A . Here, each rate parameter (r, k R off , k R on , and g) has a physical interpretation (Fig. 1B) as an element that can be tuned independently by genetic manipulation. The effect of promoter architecture on mean levels of gene expression is well established in prokaryotes, where thermodynamic models successfully predict gene expression as a function of promoter architecture (13) (14) (15) . However, the associated predictions for how transcriptional noise depends on these parameters remain untested in any systematic way. In direct contrast to such models, some high-throughput experiments have culminated in the assertion that the cell-to-cell variability in gene expression is "universal," dictated solely by the mean level of expression and insensitive to the details of the promoter driving the expression (3, 5, 6) .
To confront this divide, we constructed a library of synthetic promoters driving a LacZ reporter in E. coli and measured the resulting mRNA copy number distributions using single-molecule mRNA fluorescence in situ hybridization (FISH) (16). Our approach ensures that differences in promoter sequence between constructs have clear interpretations in terms of the molecular parameters underlying transcription (e.g., transcription factor unbinding rate, basal transcription rate). This allows us to directly compare predictions of models incorporating those parameters with experimentally observed mRNA distributions, and hence to directly link the molecular events underlying transcription with observed variability in gene expression.
For the case of constitutive expression, shown schematically in Fig. 1A , mRNA transcripts are produced and degraded stochastically at rates r and g, respectively, with constant probability per unit time. It can be shown (17) that the resulting steady-state mRNA copy number distribution is given by a Poisson distribution with mean r/g. In the following experimental results, we use the Fano factor, defined as the variance divided by the mean, to characterize variability in gene expression. This metric reports the fold change in the squared coefficient of variation (CV 2 = variance/mean 2 ) with respect to a Poisson process, for which CV 2 Poisson = 1/mean; hence, CV 2 / CV 2 Poisson = variance/mean. Therefore, the predicted Fano factor for constitutive expression equals 1 identically. However, this analysis is incomplete: The schematics of Fig. 1A represent the dynamics of the stochastic processes (transcription factor binding and unbinding, mRNA degradation, transcription initiation) that contribute to so-called "intrinsic" variability in gene expression, but do not account for the fact that rate parameters such as the repressor binding rate k R on and transcription rate r are themselves subject to fluctuations due to cell-to-cell variability in repressor and RNAP copy numbers, respectively. Such effects, collectively termed "extrinsic variability," tend to increase the measured variability (18) .
One important contribution to extrinsic noise comes from variability in gene copy number due to chromosome replication ( Fig. 2A, bottom panel) . It can be shown (16) that the effect of gene copy number variation on the variability in expression is independent and additive to the variability predicted from transcriptional noise, such that
Gene copy number ð1Þ where 〈m〉 1 is the mean mRNA copy number from a single gene copy, and f is the fraction of 
